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ABSTRACT: For allogeneic cell therapies to reach their
therapeutic potential, challenges related to achieving scalable
and robust manufacturing processes will need to be
addressed. A particular challenge is producing lot-sizes
capable of meeting commercial demands of up to 109 cells/
dose for large patient numbers due to the current limitations
of expansion technologies. This article describes the
application of a decisional tool to identify the most cost-
effective expansion technologies for different scales of
production as well as current gaps in the technology
capabilities for allogeneic cell therapy manufacture. The
tool integrates bioprocess economics with optimization to
assess the economic competitiveness of planar and micro-
carrier-based cell expansion technologies. Visualization
methods were used to identify the production scales where
planar technologies will cease to be cost-effective and where
microcarrier-based bioreactors become the only option. The
tool outputs also predict that for the industry to be
sustainable for high demand scenarios, signiﬁcant increases
will likely be needed in the performance capabilities of
microcarrier-based systems. These data are presented using a
technology S-curve as well as windows of operation to
identify the combination of cell productivities and scale of
single-use bioreactors required to meet future lot sizes. The
modeling insights can be used to identify where future R&D
investment should be focused to improve the performance of
themost promising technologies so that they become a robust
and scalable option that enables the cell therapy industry
reach commercially relevant lot sizes. The tool outputs can
facilitate decision-making very early on in development and
be used to predict, and better manage, the risk of process
changes needed as products proceed through the develop-
ment pathway.
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Introduction
Allogeneic stem cell therapies will potentially be able to treat a
broad range of unmet medical needs ranging from dry eye
related macular degeneration to acute myocardial infarction.
They are particularly promising for treating large patient
numbers as they are obtained from a universal donor and are
thus more suited to manufacturing at large scale. To date,
commercialized allogeneic stem cell therapies include
Prochymal (Osiris, Columbia, MD) for graft-versus-host
disease, approved in Canada andNewZealand, and Cartistem
(Medipost, Seoul, Korea) for osteoarthritis, approved in
South Korea. However, several products have faced challenges
achieving scalable, robust, and cost-effective manufacturing
processes (Brandenberger et al., 2011; Grifﬁth and
Naughton, 2002; Kirouac and Zandstra, 2008; Ratcliffe
et al., 2011; Rowley et al., 2012). This has contributed to
several notable failures due to manufacturing concerns such
as high cost of goods (COG), high process variability, and loss
of efﬁcacy upon scale-up (Brandenberger et al., 2011). Hence
the commercial feasibility of cell therapies is underpinned by
the need to solve the manufacturing challenges posed by
large-scale production. This article investigates the technical
innovation required in cell expansion technologies for cell
therapy products to realize their commercial potential and
achieve the manufacturing success of biopharmaceuticals.
Biopharmaceuticals, such as monoclonal antibodies
(mAbs), have beneﬁted from the availability of large-scale
bioprocessing technologies and the associated economies of
scale (e.g., Birch and Racher, 2006; Farid, 2006; Kelley, 2007).
However, this is not currently the case for allogeneic cell
therapy manufacture due to its relative infancy as well as the
inherent complexities of manufacturing living cells as the
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ﬁnal product. In contrast to mAbs, only a limited number of
cases of xeno-free cell culture media for cell therapy products
have been reported (Lindroos et al., 2009; Rajala et al., 2010).
Additionally, the culture can also include feeder cells to
promote growth. Although cell lines used to generate mAbs
are adapted to suspension culture, most cell therapies require
adherent culture. This introduces challenges for scale-up to
commercial demands. Following expansion and potential
differentiation of cell therapy products, the cells are typically
washed and centrifuged for cell concentration and recovery.
Large-scale centrifuges such as disc stacks (Kempken
et al., 1995) used in mAb manufacture are not suitable for
the processing of shear-sensitive cells, and hence the use of
alternative single-use recovery equipment such as closed
continuous ﬂuidized bed centrifuges (e.g., kSep1 Systems,
Durham, NC) is being explored. The transportation of cell
therapy products is also more complex since the product
cannot be lyophilized (freeze-dried) as is the case with mAbs;
cell therapy products are typically delivered either fresh or
cryopreserved (frozen). Both delivery options necessitate
costly cold chains with the fresh state requiring careful and
timely inventory management between manufacturing sites
and the clinic and the cryopreserved state requiring clinics to
maintain the frozen state in expensive freezers until the time
of patient administration. Cryopreservation is more typical
for allogeneic cell therapy treatments given the beneﬁts of
“off-the-shelf” inventory when creating many doses per lot to
treat large numbers of patients. Considering facility design
distinctions, although single-use technologies are increasing-
ly being adopted in mAb manufacture for vessels typically
below 2000L, their adoption is essential in cell therapy
bioprocessing due to sterility concerns (Lapinskas, 2010). In
contrast to the well-established mAb sector, the poor
automation, labor-intensive, and more open nature of cell
therapy manufacture makes it more prone to operator-
mediated variability (Lopez et al., 2010), and contamination
risks. Closed and automated technologies are now becoming
available to address the need for greater process robustness
and reproducibility.
Table I highlights several allogeneic cell therapy treatments
and their current phase of development. Most are in the
clinical trials stage. To date, allogeneic cell therapy products
in development have mainly consisted of mesenchymal stem
cells or mesenchymal progenitor cells derived from the bone-
marrow (Kebriaei et al., 2009; Goldschlager et al., 2011; Vaes
et al., 2012), umbilical-cord blood (Jung et al., 2011), liver
(Christ and Stock, 2012), or adipose (DelaRosa et al., 2012).
Promising results have also been observed for cells
differentiated from embryonic stem cells such as retinal
pigment epithelial cells (Schwartz et al., 2012), or from
fetuses for neuronal stem cell production (Miljan and
Sinden, 2009; Tamaki et al., 2002). Table I highlights that the
doses (cells/patient) typically used for cell therapy products
currently range from 105 cells for indications such as dry eye
related macular degeneration to 109 cells for liver disease,
GvHD or cardiac disease (e.g., infarction; Reinecke
et al., 2008). Accordingly, a maximum dose of 109 cells is
investigated in this study.Most companies in clinical trials are
using 2-D multi-layer vessels (e.g., 10-layer Cell Factories
(Nunc, ThermoFischer Scientiﬁc, Waltham, MA) Cell-
STACKs (Corning Incorporated Life Sciences, Tewksbury,
MA) as their main expansion technology (Rowley
et al., 2012). It is estimated that up to 1012–1013 cells will
need to be produced per lot to meet commercial demands of
high dose cell therapies. This would represent the use of
10,000–100,000 10-layer vessels per lot (values calculated by
the model described in this article). However, only 50–100
vessels can be handled per lot due to the need to perform
labor-intensive handling tasks, rendering this type of system
unsuitable for large-scale production.
The need for closed systems to limit the potential points of
contamination, to produce more cells per unit footprint, and
for greater upstream production control has driven the
production of compact multi-layered systems (e.g., HYPER-
Stack (Corning, Incorporated Life Sciences, Tewksbury,
MA)), multi-layer bioreactors (e.g., Integrity Xpansion unit
(ATMI, Danbury, CT)), and scalable microcarrier-based
bioreactor systems. To successfully meet higher future
demands, it is necessary to determine the practical and
economic feasibility of each technology.
To date, there has been a limited number of studies
addressing impact on costs and expansion technology
limitations in the cell therapy industry. Hambor (2012)
identiﬁed the probable need for increasing automation and
controlled bioreactor systems for the production of clinical
grade cell therapy products. Automation has been advanced
by the introduction of robotically controlled equipment such
as TAP Biosystems’ SelectT and CompactT systems, which
increase the potential of T ﬂasks. Prior studies estimating the
number and type of expansion technologies required to meet
a demand (Rowley et al., 2012; Want et al., 2012) were solely
based on technical inputs such as surface area, size, and
density. In another study, based on interviews and various
model assumptions, Malik (2012) estimated the cost to
produce allogeneic cell therapy products for a ﬁxed demand
of 2,500 doses/year, where a single dose represented 108
mesenchymal stem cells using T-ﬂasks with automation.
This article presents an integrated decisional tool combining
bioprocess economics and optimization for addressing cell
therapy manufacturing challenges. The detailed cost model
accounts for both technical inputs such as media requirements
as well as ﬁnancial inputs such as resource costs. The
bioprocess economics model presented in this article focuses
on the upstream processing cost of goods (COGUSP)
components that are expected to be more affected by the
choice of different expansion technologies for allogeneic cell
therapy manufacture, that is, raw materials (particularly cell
culture media and single-use technologies), labor, and
depreciation of equipment directly related to the cell expansion
step. It also incorporates QC costs associated with lot release
testing such that different manufacturing options in terms of
lot size and number of lots per year can be compared.
The novelty of this work lies in the integration of
bioprocess economics and optimization approaches to
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systematically assess the economic competitiveness of planar
and microcarrier-based cell expansion technologies, predict
the optimal and most cost-effective technology for different
scales, identify gaps in the available technologies and predict
future performance targets necessary to meet commercial
demands for cell therapies.
Tool Description
Overview
The allogeneic cell therapy manufacturing challenge ad-
dressed in this article is to meet a demand determined by
estimated dose (number of cells) with a process where
performance can be determined by seeding and harvest cell
densities, number of expansion stages, and yield. The goal is
to identify the optimal type and size of cell expansion
technology to be used at each expansion stage, to help ensure
that the COGUSP is minimized and demand targets are met.
A decisional tool was developed to address this challenge,
which integrates a bioprocess economics model, an optimi-
zation algorithm and a database, and is implemented in C#
(C-sharp) using the .NET framework (Microsoft1 Visual
Studio 2010, Microsoft Corporation, Redmond, WA) linked
to Microsoft1 Access (Microsoft Corporation). The bio-
process economics model predicts multiple technical and
Table I. Characteristics of allogeneic cell therapies currently under development.
Indication Cell types under investigation Dose for clinical trials (cells/dose)a
Acute kidney injury Bone-marrow derived hMSCs 2 108 [1]
Acute myocardial infarction Bone marrow or other nonembryonic tissue source-derived Multistem 0.2, 0.5, 1 108 [2]
Chronic Discogenic Lumbar
Back Pain
Bone-marrow derived adult mesenchymal precursor cells 0.6–1.8 107 [1]
Congestive heart failure Bone-marrow derived adult mesenchymal precursor cells 1.5 108 [3]
Critical limb ischemia Placenta-derived PLX-PAD stromal cells (hMSC-like) 1.5–3 108 [4]
Crohn’s disease Adipose-derived expanded stem cells (eASCs); Bone-marrow-derived
hMSC
2, 4 107 [5]; 6–12 108 [6]
Dry eye related macular
degeneration
Embryonic Stem Cell-Derived Retinal Pigment Epithelial (RPE) Cells 0.5–2 105 [1]
Graft vs. host disease Umbilical cord blood-derived hMSC; Bone-marrow-derived hMSC;
Bone marrow or other nonembryonic tissue source-derived
Multistem
1–5 108 [1]; 1.6 109 [1]; 0.5–1 109 [7]
Intracerebral hemorrhage (ICH) Bone-marrow derived hMSCs 7.8 106 [1]
Ischemic stroke Human foetal brain stem cell-derived hNSC; Bone-marrow-derived
hMSC; Bone-marrow derived hMSC
2 107 [8]; 0.5 1.5 108 [1]; 2 108 [1]
Liver disease Adipose-derived stromal cells 0.1–1 109 [1]
Osteoarthritis Bone-marrow- derived hMSC; Umbilical cord blood-derived hMSCs
(hUCB-MSCs)
5–15 107 [1]; 3.5 107 [11]
Peripheral vascular diseases Menstrual blood-derived Endometrial regenerative cells (hMSC-like) 0.25–1 108 [1]
Prostate cancer Prostate tumour-derived cancer cell line 2–4 107 [12]
Rheumatoid arthiritis aggravated Adipose-derived expanded stem cells (eASCs) 1–4 108 [1]
Spinal cord injury hESC-derived oligodendrocyte progenitor cells; Foetal-derived hNSCs;
Brain-derived hNSCs
2 106 [13]; 2 107 [10]; 1 108 [13]
Type I diabetes Bone-marrow-derived hMSC 6 108 [6]
Type II diabetes Bone-marrow derived adult mesenchymal precursor cells 0.1, 0.3, 1, 2 108 [14]
Ulcerative colitis Bone-marrow-derived multipotent adult progenitor cell (MAPC) 1.8 108 [11,15]
aAll doses are relevant to the phase of the trial reported in the literature source indicated in brackets. 100kg body weight was assumed where relevant.
http://clinicaltrials.gov/.
1. http://clinicaltrials.gov/.
2. Penn et al. (2012).
3. http://202.66.146.82/listco/au/mesoblast/analystrep/ar111115.pdf.
4. http://www.pluristem.com/CPY155053[1].pdf.
5. http://www.cellerix.com/Press-Room/Last-News/CELLERIX-DISCLOSES-RESULTS-OF-PHASE-IIa-CLINICAL-TRIAL-OF-Cx601-PRODUCT.
6. http://www.osiris.com.
7. http://newsroom.athersys.com/news/athersys-announces-positive-results-of-multistemR-clinical-trial-for-hematopoietic-stem-cell-transplant-support-
and-prevention-of-graft-versus-host-disease.
8. http://www.iii.co.uk/investment/detail/?display¼discussion&code¼cotn%3ARENE.L&it¼le&action¼detail&id¼9770249.
9. WIPO: WO/2008/002523.
10. http://www.reuters.com/ﬁnance/stocks/STEM.O/key-developments/article/2601553.
11. http://advbiols.com/documents/Bravery-AreBiosimilarCellTherapiesPossible.pdf and http://clinicaltrials.gov/ct2/show/record/NCT01041001 (500ml/cm2 of
cartilage defect at 5 106 cells/ml, and assuming the area for treatment is similar to that for knee sports injury (Mason and Dunnill, 2009) i.e. 2 7 cm2 or 14 cm2.
12. http://cdn.intechopen.com/pdfs/24252/InTech-Entering_a_new_era_prostate_cancer_immuno_therapy_after_the_fda_approval_for_sipuleucel_t.pdf.
13. http://stemedica.blogspot.co.uk/.
14. http://www.mesoblast.com/newsroom/asx-announcements/archives/ (10 November 2011).
15. http://www.celltherapysociety.org/uploads/ﬁles/Annual%20Meetings/2012/Final%20Presentations%20PDF/Wed%201230.3%20Pinxteren%20Grand%20C.
pdf.
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ﬁnancial performance measures of a particular process
conﬁguration. The optimization algorithm generates alter-
native process conﬁgurations and uses the bioprocess
economics model to evaluate each alternative. The database
stores input data to be used by the bioprocess economics
model and optimization algorithm in addition to the output
data that results from running those procedures. The tool also
comprises a graphical user interface. The focus of this article
is on the development and application of the core
components of the optimization framework for the cell
expansion stage in allogeneic cell therapy manufacture, as
illustrated in Figure 1.
Bioprocess Economics Model
The bioprocess economics model was conﬁgured to perform
equipment sizing and resource consumption calculations and
consequently to determine the value of the upstream
processing COG per dose (COGUSP/dose) of a particular
process conﬁguration. In this article, COGUSP/dose com-
prised the annual direct (materials, labor and QC) and
indirect (equipment depreciation) operating costs divided by
the annual product output (number of doses/year). Key to the
evaluation of the cost of a cell expansion process is the type of
technology used and the number of units necessary to obtain
the required number of cells. For a given product with doseM
(cells/dose) and harvest density dharvestcell (cells/cm
2) and a
manufacturing lot size Dlot (doses/lot), the number of units of
a particular technology i required for the last cell expansion
stage N, ui;N was calculated by the bioprocess economics
model as follows:
ui;N ¼ D
lotM
ydharvestcell ai
& ’
ð1Þ
where y is the overall yield of the downstream operations
(e.g., volume reduction, ﬁlling) and ai is the growth surface
area (cm2) per technology i unit. For microcarrier-based
systems using single-use bioreactors (SUB), the value of ai is
calculated by:
ai ¼ amicrocarriercmicrocarrierVbior;il ð2Þ
where amicrocarrier is the growth surface area per gram of
microcarrier (cm2/g), cmicrocarrier is the concentration at
which the microcarriers are seeded into the bioreactor (g/L),
Vbior,i is the total volume of the bioreactor and l is the
bioreactor working volume ratio.
The type of technology to be used in the expansion seed
train was determined by a set of rules that take into account
Figure 1. Cell expansion optimization framework.
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the compatibility between different technology types. The
number of technology units i to be used in the expansion seed
train (stage j¼ 1,…, N 1) was calculated by:
ui;j ¼ d
seeding
cell aT
dharvestcell ai
& ’
ð3Þ
where T is the technology used in stage jþ 1 and dseedingcell is the
cell seeding density (cells/cm2).
Once the type of technology and number of units to be
used at each expansion stage were deﬁned, the bioprocess
economics model calculated the value of the objective
function COGUSP/dose as follows:
COGUSP=dose ¼
X
j
Cannualmat;j þ Cannuallab;j þ CannualQC;j þ Cannualdep;j
Dannual
ð4Þ
where Cannualmat;j , C
annual
lab;j , C
annual
QC;j , and C
annual
dep;j are the total annual
material, labor, QC, and equipment depreciation costs,
respectively, for each expansion stage andDannual is the annual
demand (doses/year). The demand can be obtained by
different combinations of lot size (doses/lot) and number of
lots per year, as explored in the case study.
The material costs were designed to account for the
consumables and media directly used in each expansion
stage:
Cannualmat;j ¼ ui;jðpconsum;i þ Vmedia;iaipmediaÞLannual ð5Þ
where pconsum,i, Vmedia,i, and ai are the unit consumables price,
the media requirements (mL/cm2) and the surface area of
technology i, respectively, pmedia is the media price and L
annual
is the number of lots per year. For microcarrier-based
systems, the material costs included media costs, the cost of
the microcarriers and the costs with SUB bags:
Cannualmat;j ¼ ui;jðVbior;ilðpmedia þ cmicrocarrierpmicrocarrierÞ
þ pSUB;iÞLannual ð6Þ
where pmicrocarier is the unit price of microcarriers ($/g) and
pSUB,i is the price of a SUB bag of size i.
Labor costs were based on the total operator time required
to perform manual cell expansion tasks including seeding,
feeding, and harvesting:
Cannuallab;j ¼ ui;jðtseed;i þ tfeed;i þ tharvest;iÞChopLannualð1þ bÞ ð7Þ
where tseed,i, tfeed,i, and tharvest,i represent the time required for
an operator to perform the manual operations associated
with seeding, feeding, and harvesting of cell expansion
vessels, Chop is the labor hourly wage, and b is a multiplier to
account for other labor costs (e.g., supervisors and
management).
QC costs comprised the range of studies required for
testing a lot prior to release and a ﬁxed value (ClotQC) was
incurred per batch:
CannualQC;j ¼ ClotQCLannual ð8Þ
The indirect costs considered here were the equipment
depreciation costs for equipment directly related to the
handling of the cell expansion technologies. This value is
proportional to the total facility-dependent overhead costs.
The cost of ancillary equipment (e.g., controllers, automation
units), incubators and biosafety cabinets was calculated
taking into account their capacity and unit price and the total
was divided by the depreciation period to obtain the annual
equipment depreciation costs:
Cannualdep;j ¼
ui;j=U anc;i
 
panc;iþ ui;j=U incub;i
 
pincub;iþ ui;j=UBSC;i
 
pBSC;i
tdep
ð9Þ
where Uanc,i, Uincub,i, and UBSC,i are the capacities of the
different types of equipment in terms of number of units of
technology i each can handle per lot, panc,i, pincub,i, and pBSC,i
are the corresponding prices and tdep is the depreciation
period. The capacity of a biosafety cabinet (UBSC,i) was
derived assuming that it could only be used by one operator at
a time.
The value of COGUSP/dose was then used by the
optimization algorithm to select the most cost-effective
technology, as described in the following section.
Optimization Algorithm
The optimization algorithm implemented in the tool
consisted of an enumeration procedure that screened
through all the cell expansion technologies and selected
the most cost-effective alternative for meeting pre-deﬁned
manufacturing constraints. The cost-effectiveness was
evaluated by the bioprocess economics model, as described
in the previous section. The manufacturing constraints
deﬁned the maximum number of cell expansion technology
units that could be handled per lot in the last expansion stage
such that:
ui;N  umax ð10Þ
where umax is a user-deﬁned parameter that can have different
values for different technology types. As shown in Figure 1,
the optimal solution determined by the tool was the
expansion technology that gave rise to the lowest COGUSP/
dose within the manufacturing constraints deﬁned by
Equation (10). In some cases, there may be scenarios where
none of the candidate technologies are able to meet the
maximum number of units constraint, and this is discussed
in the Results and Discussion section.
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Case Study Setup
An industrially relevant case study was set up to illustrate and
examine the ability of the proposed tool to discover optimal
cell expansion strategies for the design of cell therapy
manufacturing processes. The case study focuses on therapies
using mesenchymal stem cells derived from bone marrow.
Different allogeneic cell therapy products are considered,
with doses within the range identiﬁed from Table I and with
potential for high commercial demands of up to
500,000 doses/year (e.g., assuming a 10% market share of a
5million patient population, as indicated for heart disease by
Mason and Dunnill, 2009). The goal of the study was to
investigate which commercially available technologies would
be the most cost-effective for meeting production demands.
This analysis would allow for resources to be allocated
appropriately for relevant experimental validation and
optimization of the most promising technologies at earlier
stages of development, thus potentially reducing risk.
Table II presents the different planar technologies
evaluated for cell expansion and speciﬁc characteristics of
each candidate, generated using information from literature,
vendor communications, as well as advice sought from
industrial experts so as to capture trade-offs in surface area,
cost, equipment, and labor requirements. Six types of planar
technologies were considered and generic names were given:
T-ﬂasks (T), multi-layers (L), compact ﬂasks (cT), compact
multi-layers (cL), multi-layer bioreactors (bL), and hollow-
ﬁber bioreactors (HF). Examples of associated commercial
names are shown in the footnote of Table II. Each type of
technology is sized by surface area or the number of layers
and this is represented by numerical values (e.g., T175 is a T-
ﬂask with 175 cm2 of surface area and L-10 has 10 layers). The
use of additional automation equipment is indicated by the
sufﬁx “(aut),” as in the case of L-40 and cL-120. It is assumed
that these two technologies have a similar footprint and 4
units can be handled simultaneously by a robot (automated
cell factory manipulator, ACFM) performing seeding (ﬁlling)
and harvesting (emptying) operations. The use of micro-
carriers in SUBs was also considered as a candidate
technology for cell expansion but only for those demand
scenarios where the use of planar systems would exceed the
maximum number of units imposed by Equation (10). This
was implemented to reﬂect the current industrial preference
for planar cell expansion technologies. The parameters used
for different SUB sizes are presented in Table III. The values
for the surface area (cm2/g) and density (g/L) of the
microcarrier-based technology assumed in the case study
were based on literature data. Ranges of 360–5,500 cm2/g and
3.3–9.3 g/L have been reported in the literature for the
expansion of adult stem cells using non-porous micro-
carriers, as shown in Table IV. The mid-point values of 2,930
cm2/g and 6.3 g/L were used for the microcarrier surface area
and density, respectively. Although these values were initially
used to estimate the required size and number of SUBs to
meet large demands, a sensitivity analysis was subsequently
carried out in order to determine the impact of the variation
of the microcarrier surface area on the optimal expansion
strategy across different demand scenarios.
The tool was run for different scenarios in terms of annual
demand (1,000–500,000 doses/year) and manufacturing lot
size (50–10,000 doses/lot) in order to determine the most
cost-effective cell expansion technologies and identify the
limits of existing technologies. The key process and cost
parameters used in the model for the case study are shown in
Table III.
Results and Discussion
This section presents insights from the cost modeling and
optimization studies for adherent cell expansion technologies
for allogeneic cell therapies. The economic competitiveness
of commercially available planar and microcarrier-based cell
expansion technologies is initially discussed across different
production scales. A sensitivity analysis study is then
presented to identify the most critical model parameters
and hence the key cost drivers. A technology S-curve is
proposed to visualize the performance trajectories of each
technology. The analysis is extended to identify targets for
microcarrier-based technologies to meet potential commer-
cial lot sizes.
Economic Competitiveness of Commercially Available
Cell Expansion Technologies
The tool was used initially to determine the cost-effectiveness
of commercially available planar expansion technologies for
different scales. Figure 2 illustrates how the optimal cell
expansion technology changes across a matrix of demands
and lot sizes for four different doses (106–109 cells/dose); the
doses are representative of the range of doses reported for
allogeneic cell therapy treatments in Table I. Figure 2e shows
the required number of lots necessary to meet the demand,
for each combination of demand and lot size. As the focus of
the article is on commercial manufacturing, only
manufacturing options with a minimum of 10 and a
maximum of 200 lots/year were considered. Each individual
matrix cell shows the optimal technology for a particular
combination of demand and lot size, and the number of units
required per lot (within brackets) for the ﬁnal stage of the
expansion process train. For L-40 and cL-120 the values
shown within brackets represent the number of automated
units used (i.e., number of robots (ACFM) handling up to 4
units each).
A closer examination of Figure 2a reveals trends in the
characteristics of the optimal technologies. Along the matrix
diagonal, the cells per lot increase and the optimal
technologies have increasing surface areas per unit. Moving
vertically down the matrix in Figure 2a, the number of lots
per year increases and the optimal technologies switch to
those that can be automated. For example, for a lot size of 500
doses (Fig. 2a) the tool predicts a shift in competitiveness
from four L-10 vessels to one ACFM with four L-40 units.
This is because labor costs increase with the number of lots
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and thus, having automation reduces its contribution to the
ﬁnal COGUSP/dose value. In addition, as the dose size
increases (Fig. 2a–d), a greater number of cells is produced
per lot and the matrices show the increasing need for
technologies with larger surface areas at smaller lot sizes. This
is observed, for example, by the solution space of the matrix
shifting to the left when moving from Figure 2a (106 cells/
dose) to Figure 2b (107 cells/dose).
The data used to generate the optimal matrices were
further examined so as to understand the inﬂection points
where the ranking of competing technologies switches
(Fig. 3a) and the associated cost drivers inﬂuencing the
selection of the optimal technologies (Fig. 3b). Figure 3a
presents a cost comparison between L-40 and cL-120 in
Figure 2b (107 cells/dose) across the matrix row with a
demand of 10,000 doses/year. The ﬁgure also includes a
comparison with L-10 vessels, as this technology represents
the typical manufacturing option currently being used in
industrial settings. Figure 3b illustrates that for small lot sizes
of 50 doses/lot, QC costs dominate the COGs (>50%)
followed by labor (21–33%) and material costs (14–25%),
due to the high number of lots (200) necessary to meet the
demand. The ﬁxed equipment depreciation costs are not
signiﬁcant since they are spread over several lots. The optimal
solution L-40 (represented by point A) achieves cost savings
through minimizing material costs given its lower consum-
able unit price relative to cL-120. L-10 has the largest
proportion of labor costs due to the manual handling of the
vessels, while L-40 and cL-120 are automated. For the
opposite scenario of fewer but larger batches (1,000 doses/
lot), the technology ranking switches from L-40 to cL-120.
QC costs no longer dominate since they are proportional to
the number of lots. Larger lots require a higher number of
vessels and hence the optimal technology, cL-120 (point B),
achieves cost savings by minimizing the total number of units
required, given its larger surface area per unit. The use of two
automated units (cL-120), instead of ﬁve (L-40), results in
lower equipment depreciation and labor costs. (Although
material costs dominate at these larger scales, they are similar
for both technologies at this lot size and demand
combination.)
The impact on COGUSP/dose of using L-10 vessels instead
of the optimal technologies determined by the tool is
signiﬁcant, with a 17% increase in the COGUSP/dose value
relative to the optimal solution for 50 doses/lot and 138% for
Table III. Key process and cost assumptions used in the case study.
Process parameter Value
Process data
Number of expansion stages (N) 4
Seeding density dseedingcell
 
3,000 cells/cm2
Harvest density dharvestcell
 
25,000 cells/cm2
Overall process yield (y) 85%
Maximum # units/lot (umax for planar technologies) 80
Maximum #SUBs/lot (umax for microcarriers) 8
Microcarrier surface area (amicrocarrier) 2930 cm
2/g
Microcarrier seed concentration (cmicrocarrier) 6.3 g/L
Single-use bioreactor working volume ratio (l) 75%
Cost parameter Value
Cost data
Cell culture media (pmedia) $150/L
Microcarriers (pmicrocarriers) $5/g
Single-use bioreactor bag (pSUB(Vbior)) $2,000 (20L); $4,500 (200L); $5,850 (500L);
$8,850 (1000L); $10,500 (2000L)
Single-use bioreactor support equipment (panc
for microcarriers (Vbior))
$185,000 (20L); $215,000 (200L); $320,000 (500L);
$425,000 (1000L); $575,000 (2000L)
L-40/cL-120 incubator (pincub for L-40 and cL120 systems) $30,000
Double stack incubator (pincub for other systems) $17,835
Biosafety cabinet (pBSC) $17,000
Operating labor Chop
 
$200/h
QC testing ClotQC
 
$10,000/lot
Other labor cost multiplier (b) 2.2
Depreciation period (tdep) 10 years
Table IV. Reported ranges for microcarrier surface area and density
values for mesenchymal stem cells.
Type of microcarrier
Surface area
(cm2/g) Density (g/L)
Non-porous 360–5,500 3.3–9.3
Porous 11,000–15,000 1–5
Non-porous¼Cytodex I, II, III (GE Healthcare), MicroHex (Thermo
Fisher Scientiﬁc), and Plastic (SoloHill Engineering).
Porous¼CultiSpher S and G (Percell Biolytica), Cytopore II (GE Health-
care).
Sources: Vendors (Percell Biolytica, GE Healthcare, Thermo Fisher Scientiﬁc,
SoloHill Engineering), Sart et al. (2010),Wu et al. (2003), Rubin et al. (2007),
Yang et al. (2007), Frauenschuh et al. (2007), Zayzafoon et al. (2004), Meyers
et al. (2005), Whitford and Fairbank (2011).
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1,000 doses/lot. Labor costs dominate due to the manual
handling of large numbers of units. For 1,000 doses/lot,
74 units/lot are required and therefore the maximum
number of units constraint is still met (80). However for
a dose of 108 cells, 740 units would be required per lot
leading not only to the violation of the maximum number
of units constraint but also to a 232% increase in COGUSP/
dose relative to the optimal strategy. These insights are
valuable for a company currently using L-10 vessels for an
early phase product since they provide greater understand-
ing of the ﬁnancial and logistical impact of continuing to
use such vessels for commercial production. Hence such
analysis can be used to anticipate early in development, the
commercial feasibility of processes and thus prioritize
investment and development efforts in alternative
technologies.
Figure 2. Optimal cell expansion technologies across a matrix of demands and lot sizes for a dose of (a) 106 cells, (b) 107 cells, (c) 108 cells, and (d) 109 cells. Each matrix cell
shows the name of the optimal technology for a particular combination of demand and lot size and the number of units required per lot (inside brackets). For L-40 and cL-120 the value
inside brackets represents the number of automated units required (i.e., number of sets of 4 units). The use of microcarriers was allowed only when the maximum number of units
was exceeded for all planar technologies. The gray areas represent production scenarios that cannot be met by any candidate technology. Matrix (e) shows the number of lots run
per year for each combination of demand and lot size.
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Point B in Figure 3a represents the most cost-effective
manufacturing strategy for meeting the demand of
10,000 doses/year for a product with 107 cells/dose and this
highlights the importance of an efﬁcient equipment and
facility utilization to lower depreciation costs per dose. The
optimal manufacturing conﬁguration for a lot size of
1,000 doses/lot is to run 10 lots/year using two automated
cL-120 units/lot for the ﬁnal (4th) stage of cell expansion. The
expansion seed train generated by the tool for this
conﬁguration, using the rules deﬁned in the Bioprocess
Economics Model section, was: three T-500 units for stage 1,
six cT units for stage 2, and four cL-36 units for stage 3. The
model assumed that enough cells are available from a master
cell bank to seed the T-ﬂasks at stage 1.
Microcarrier-based systems were only used in production
scenarios that could not be met by any planar technologies
because the number of units required per lot exceeded the
maximum limit constraint (i.e., 80 units), as shown in the last
column of Figure 2c and in most columns of Figure 2d.
However, the tool outputs also identiﬁed the demands where
the base case non-porous microcarrier-based systems would
also exceed the number of units constraint (i.e., 8 units) as
illustrated by the gray area in Figure 2d. This emphasizes the
need for technologies with larger growth surface area for
expansion and indicates that available technologies are not
feasible for large lot sizes with high dose products. Micro-
carrier SUBs are more capable of matching very high
demands and lot sizes, but the gray region indicates that a gap
still exists for theoretical maximum lot size scenarios
(Fig. 2d). The use of seven 500L SUBs per lot allows the
manufacture of up to 5,000 doses/lot for a dose of 108 cells
(Fig. 2c) but this value drops to 1,000 doses/lot for higher
dose values of 109 cells (Fig. 2d). To be able to meet the
maximum demand of 10,000 doses it would be necessary to
run 17 2000L SUBs per lot, which violates the constraint
imposed on the maximum number of SUBs that can run in
parallel (8).
The previous analysis assumed that planar cell expansion
technologies were preferred over microcarrier-based systems.
If no such preference existed, then the cost savings of using
microcarriers in SUBs could be substantial. For example, the
use of 1 20L SUB instead of 1 cL-120 for the production
of 500 107 cells/lot (Fig. 2b, lot size¼ 500, demand
¼ 100,000) would represent a decrease in COGUSP of 40%,
while the use of 1 1000L SUB instead of 50 cL-120 to
produce 2.5 1011 cells/lot (Fig. 2c, lot size¼ 2,500, demand
¼ 50,000) would allow savings of 73%.
Sensitivity Analysis to Identify Key Cost Drivers
A sensitivity analysis on the key yield parameters (harvest
density and DSP yield) and resource costs was carried out to
identify the most critical parameters in the bioprocess
economics model that inﬂuence the cost outcome. The
tornado diagrams in Figure 4 represent the impact of
changing each of the parameters by30% on COGUSP/dose.
Figure 4a–c represents the use of different planar cell
expansion technologies (L-10, Fig. 4a; L-40, Fig. 4b; cL-120,
Fig. 4c) for the manufacturing scenario highlighted in
Figure 3with dose¼ 107 cells, annual demand¼ 10,000 doses
and lot size¼ 1,000 doses. Figure 4d shows the tornado
diagram for a production scenario using 2000L SUB with
microcarriers, where microcarrier-related model parameters
were also included.
For planar technologies, the harvest density (amount of
cells harvested per cm2) was the parameter with the highest
impact on the value of COGUSP/dose. This is to be expected
since the harvest density dictates the yield of the cell
Figure 3. Comparison between L-10, L-40, and cL-120 for a fixed demand of 10,000 doses/year and across different lot sizes for a dose of 107 cells in terms of (a) % change in
COGUSP/dose relative to optimal technology and (b) COGUSP structure. (a) and (b) are the optimal solutions for lot sizes of 50 and 1,000 doses.
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expansion technologies and hence the number of expansion
units required. Of the resource costs, the labor rate was found
to be signiﬁcant for L-10 (Fig. 4a) due to the labor-intensive
nature of the handling tasks but not so important for L-40
and cL-120 (Fig. 4b and c) due to the automation of these
tasks. Instead, the vessel price was found to be the most
signiﬁcant resource cost driving the COGUSP/dose value for
the larger automated vessels (L-40 and cL-120). For
manufacturing scenarios where microcarriers are used in
2000L SUB, the most critical model parameter affecting
COGUSP/dose was found to be the microcarrier surface area
(Fig. 4d), followed by harvest density and microcarrier
density. All these parameters inﬂuenced the amount of cells
that could be obtained from a particular setting leading to an
increase or decrease in the number of units required to meet
the demand. The impact of changes in these critical
parameters on the performance of the microcarrier option
was then explored further (see Figs. 5 and 7). Media price was
also found to be signiﬁcant due to the larger volumes of
media handled in SUB relative to planar technologies.
Although the base case process analyzed in the article is
representative of current mesenchymal stem cells
manufacturing processes, experimental validation of the
key model parameters would be necessary to apply the
proposed modeling framework to a speciﬁc cell therapy
process.
Figure 4. Tornado diagrams showing the sensitivity of COGUSP/dose to the key bioprocess economics model parameters. Results are shown for manufacturing scenarios
where the following cell expansion technologies are used per lot in the base case scenario: (a) 74 L-10 vessels, (b) 19 L-40 handled by five ACFMs, (c) 8 cL-120 handled by two
ACFMs, (d) 5M-2000L bioreactors with microcarriers. The corresponding values of dose, demand, and lot size are: (a), (b), (c) dose¼ 107 cells, demand¼ 10,000 doses/year, lot
size¼ 1,000 doses/lot, (d) dose¼ 109 cells, demand¼ 50,000 doses/year, lot size¼ 2,500 doses/lot. The base case values of each parameter are shown in Table III. For each
parameter the base case values were changed by 30% to generate the plots. The vertical axis intersects the horizontal axis at the base case value in each diagram.
Figure 5. Impact of microcarrier surface area on the optimal cell expansion
strategy across different lot sizes (number of cells produced per lot). The numbers
inside the plot represent the number of units of the optimal technology required for the
last expansion stage, for each combination of microcarrier surface area and number of
cells produced per lot. For L-40 and cL-120, the value represents the number of
automated units required (i.e., number of sets of 4 units). The gray areas represent
production scenarios that cannot be met by any candidate technology.
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The microcarrier-SUB results were obtained assuming an
average non-porous microcarrier surface area of 2,930 cm2/g.
Although this is within the range of values found in the
literature for different microcarrier types, it might represent
an overestimation of the performance of some non-porous
systems. Hence, the sensitivity analysis of this parameter was
extended by assigning to it different values within the range
360–2,930 cm2/g and running the optimization algorithm to
ﬁnd the optimal expansion technology, across different lot
sizes. In this study no preference of planar technologies over
microcarriers was included and the results are presented in
Figure 5. The last column of the heat map corresponds to a
microcarrier surface area of 2,930 cm2/g, that is, the value
assumed for the previous analysis, and shows that planar
technologies are only optimal for smaller lot sizes of up to
5 108 cells. For production scenarios of 1 109 to 3 1010
cells/lot, small 20L SUBs with microcarriers become the most
cost-effective option and for higher production scales the use
of larger SUBs is required. As the microcarrier surface area
decreases (moving to the left in the plot), a larger number of
SUBs or SUBs with larger sizes are required and planar
technologies gain competitiveness. The left extreme of the
heat map represents the worst performance of microcarriers
in terms of surface area. In this scenario, microcarrier-based
systems are only selected when the maximum number of
units is exceeded by planar technologies. Finally, the gray area
has a similar interpretation as in Figure 2d, that is, it
represents large production scales for doses of 109 cells that
cannot be met by any of the candidate technologies.
As indicated in Table I, some cell therapy products
currently under development have doses in the order of
109 cells and thus a step improvement in the performance of
existing cell expansion technologies is necessary so as to avoid
future failures related to manufacturing and scale-up issues.
Technology S-Curve for Cell Therapy Manufacture
Technology S-curves illustrate the introduction, growth and
maturation of innovations and have been used to analyze the
evolution of technologies in several industry sectors varying
from semiconductors to renewable energy sources
(Bowden, 2004; Schilling and Esmundo, 2009). For cell
expansion technologies, a conceptual illustration of a
technology S-curve was created by plotting the performance
of each technology in terms of billion cells achieved per lot
(when using the maximum number of units per lot) against
R&D effort/investment. The x-axis represents qualitatively
the R&D effort required for a company currently using T-
ﬂasks to change to other cell expansion technologies.
Figure 6 shows a technology S-curve built using the data
and assumptions of the tool for candidate cell expansion
technologies considered in the case study. The details of the
upper and lower limits for each technology in the S-curve and
the corresponding COGUSP estimates are presented in
Table V. For smaller lot sizes using T-ﬂasks the COGUSP
range is $49–240/million cells while for larger lots using
multi-layers the range decreases to $15–62/million cells.
Signiﬁcant economies of scale exist for very large lot sizes
using microcarriers with COGUSP values as low as $0.7–3.2/
million cells being achieved. (It should be noted that these are
the operating costs for the cell expansion step and associated
QC lot release costs and that only the equipment depreciation
Figure 6. Conceptual illustration of a technology S-curve showing the evolution of
expansion technologies used in cell therapy manufacture. The limits of each S-curve
correspond to the amount of cells achieved by the smallest and largest size of each
technology type when using the maximum number of units (80 for planar and 8 for
microcarriers). Automated multi-layers refer to L-40 and cL-120. The x-axis represents
qualitatively the R&D effort required for a company currently using T-flasks to change
to other cell expansion technologies.
Table V. Limits of S-curve and associated COGUSP values.
Technology type
Lower limit Upper limit
Size
Performance
(109 cells/lot) COGUSP
a ($/106 cells) Size
Performance
(109 cells/lot) COGUSP
a ($/106 cells)
T-flasks 80T75 0.1 240 80T500 0.9 49
Multi-layers 80 L-1 1 62 80 L-10 11 15
Compact flasks and multi-layers 80 cT 3 19 80 cL-36 31 8.5
Multi-layer bioreactors 80 bL-10 13 39 80 bL-180 229 9.2
Automated multi-layers 80 4 L-40 173 6.5 80 4 cL-120 408 5.0
Microcarriers 8M-20L 47 3.2 8M-2000L 4,708 0.7
aCOGUSP values shown here are based on the direct costs (material, labor, QC testing) and indirect costs (equipment depreciation only) of the cell expansion
process and assuming overheads are spread over 10 lots/year for all scenarios.
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component of the facility-dependent indirect costs are
included). For a dose of 109 cells the best case COGUSP
values translate into $700/dose for microcarriers and
$15,000/dose for multi-layer vessels. Given reimbursement
values could be in the order of $25,000/patient this would
result in values of COGUSP as % sales of 3% for microcarrier-
based processes to60% for multi-layer processes (assuming
single dose products). In the biologics industry typical values
for COG as % sales have been reported to range from 15% to
40% (Smith, 2012) in order to recover R&D, sales and
marketing costs whilst achieving attractive proﬁt margins.
Assuming allogeneic cell therapies will have gross margins in
line with biologics (Smith, 2012) and that COGUSP represents
at least 50% of the total COG, this would translate into
COGUSP targets for the allogeneic cell therapy industry of
$1,875–5,000/dose. Hence for the high cell doses of 109 cells/
dose, only the microcarrier-based processes would meet this
cost target and allow for a successful business model, as
predicted by the optimization tool.
The conceptual S-curve exhibits a similar trend to a typical
technology adoption curve where a limit in the performance
forces the introduction of new technologies. It shows that the
adoption of new technologies for cell therapy manufacture is
driven by the need to produce a larger amount of cells.
Analyzing cell expansion technologies from a technology S-
curve demonstrated that each technology covers approxi-
mately one log of performance in terms of lot size (billion
cells per lot) before being replaced by a newer technology. In
the case of microcarrier-based systems, two logs are covered
due to the wide range of SUB-sizes considered in this analysis
(from 20L to 2000L). The S-curve also shows that a
technology gap exists for meeting the largest anticipated
commercial lot sizes (1013 cells). The top performance target
value of 10,000 billion cells corresponds to the production
scenario of the last column of the matrix shown in Figure 2d
and it is evident from the S-curve that none of the
technologies considered in this study are able to achieve it.
Existing planar technologies are unable to achieve the next
log demand (1,000 billion cells) nor the largest value
(10,000 billion). Given the nature of microcarrier technolo-
gies and their potential for improvement, an analysis was
carried out to explore how the performance target could be
achieved in terms of operating parameters. This study is
described in the following section.
Future Performance Targets for Microcarrier Applications
The current performance level of the microcarrier-based
technology analyzed in this article is 0.5million cells/mL.
This is the result of using non-porous microcarriers with a
surface area of 2,930 cm2/g, a density of 6.3 g/L and assuming
a harvest cell density of 25,000 cells/cm2. The production
target of 10,000 billion cells/lot can be achieved through
different combinations of total bioreactor capacity and cell
concentration in the microcarrier culture. The contours in
Figure 7a represent the number of billion cells achieved per
lot (in the body of the graph) as a function of the cell
concentration (million cells/mL) present in the microcarrier
culture and the number of SUBs used per lot. The bold
contour represents the target of 10,000 billion cells/lot. This
graph can be used to drive facility design given the level of
performance of a particular technology. For example, if the
microcarrier technology is able to achieve a 5.2-fold increase
in cell concentration to 2.6million cells/mL, then a total of
three SUBs per lot would be required (represented by point A
on the graph). However, if only a 2.6-fold increase to
1.3million cells/mL was possible, then six SUBs would need
to be used per lot. Note that in order to meet the maximum
production target of 10,000 billion cells/lot using the current
performance level of 0.5million cells/mL it would be
necessary to run 17 2,000L SUBs per lot, thus signiﬁcant
cost savings could be achieved by improving the microcarrier
performance. This approach allows companies to explore the
trade-off between the cell concentration achieved in a
microcarrier culture and the number of SUBs to run per
Figure 7. Contour plots showing characteristics of required future microcarrier
performance. (a) Billion cells per lot achieved as a function of the number of 2000L SUBs
used and themillion cells/mL present in themicrocarrier culture. The bold line represents
the target of 10,000 billion cells/lot that can be achieved using different configurations
including points A and B. (b) Million cells/mL achieved in a microcarrier culture as a
function of the microcarrier density and surface area. The shaded areas highlight zones
with the same value of million cells/mL (1.3 or 2.6) that can be achieved with harvest
densities ranging from 20,000 cells/cm2 (upper limit of shaded area) to 30,000 cells/cm2
(lower limit of shaded area). X represents a possible setup to achieve 2.6 106 cells/mL.
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lot and to identify the operating conditions most suitable for
a particular process.
As the cell concentration depends on several process
parameters including harvest cell density per area, micro-
carrier surface area and microcarrier density, the impact of
each of them on the performance target was investigated and
a visual tool to aid this decision-making process was
generated. Figure 7b illustrates the million cells/mL achieved
in a microcarrier culture as a function of the microcarrier
density and surface area, and highlights the impact of the
harvest cell density per area on those parameters. Two shaded
areas are shown and these correspond to the windows of
operation to achieve 2.6 and 1.3million cells/mL, that is, to
implement the strategies represented by points A and B of
Figure 7a, respectively. A possible setup to achieve 2.6million
cells/mL is shown by point X; assuming a microcarrier with a
surface area of 8,000 cm2/g and a typical harvest density of
25,000 cells/cm2, then the required microcarrier density
would be around 13 g/L. This represents a substantial increase
relative to current performance levels, where values up to
5,500 cm2/g and 9.3 g/L have been reported for the expansion
of adult stem cells in non-porous microcarriers (Table IV).
Investment in improving the microcarrier surface area could
be an option, such as the use of porous microcarriers with
surface areas of 11,000–15,000 cm2/g (Table IV). Although
this is a valuable guide, normally at small-scale, several
microcarriers would have to be screened for attachment,
expansion, and optimal harvest from the microcarriers.
Important properties of microcarriers include size, degree of
porosity, and charge density. Sart et al. (2010) indicated that
porousmicrocarriers aremore suitable for the propagation of
mesenchymal stem cells than solid supports, and this was
thought to be due to the protective effect of porous
microcarriers shielding cells from shear. On the other
hand, it may be harder to harvest the cells from porous
microcarriers such as Cultispher S (Hyclone), than non-
porous equivalents such as Cytodex III. Thus, further
experimental optimization would have to be performed to
validate the use of porous microcarriers for the expansion of
stem cells and to resolve difﬁculties associated with cell
productivities and harvesting.
The challenges of scaling-up mammalian cell culture have
been addressed in the past by the mAb/recombinant protein
industry. Taking those lessons onboard and investing in the
development of alternative and more scalable technologies,
such as suspension culture, will be critical if cell therapy
products are to achieve the commercial manufacturing
success of biopharmaceuticals.
Conclusion
This article presents an integrated decisional tool combining
a bioprocess economics simulation engine with an optimiza-
tion procedure to identify optimal expansion technologies for
cell therapies. The application of the tool to an industrially
relevant case study on the production of allogeneic cell
therapies highlighted how the competitiveness of alternative
systems varies with production scale and identiﬁed limits of
available expansion technologies and technology gaps.
Further analysis also indicated the fold increase in
performance that would be required to reach maximum
target demands. Emphasis was placed on the use of
visualization methods to present optimal solutions across
a range of scales and windows of operation for future
performance targets. A technology S-curve for cell expan-
sion was derived with data from the tool and facilitated the
characterization of industry trends and identiﬁcation of
technology gaps. The modeling insights can be used to
prioritize the focus of future R&D investment so as to
improve the performance of the most promising technolo-
gies so that they become a robust and scalable option that
enables the cell therapy industry reach commercially
relevant lot sizes. The tool outputs can facilitate decision-
making very early on in development and may be used to
predict, and better manage, the risk of process changes
needed as products proceed through the development
pathway. Future research will include the extension of the
tool to include downstream operations and the develop-
ment of case studies to address different types of allogeneic
and autologous cell therapies.
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